Fiche centre
Instytut Centrum Zdrowia Matki Polki
Lodz — Poland
Essais liés7clinical trials
VilleLodzlocalisation
PaysPolandlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05196035
Essais cliniques associés
7| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Nivolumab | Cancer | Phase 3 | NCT06561386 | RELATIVITY1093 — A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% | RECRUITING |
| Finerenone (Kerendia, BAY94-8862) | Maladie rénale chronique | Phase 3 | NCT05196035 | FIONA — A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | ACTIVE_NOT_RECRUITING |
| Sotorasib | Cancer | Phase 3 | NCT05920356 | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | RECRUITING |
| Erenumab Dose 1 | Migraine | Phase 3 | NCT03832998 | OASIS(CM) — Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine | COMPLETED |
| SAT-3247 | Myopathies | Phase 2 | NCT07287189 | BASECAMP — Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients | ACTIVE_NOT_RECRUITING |
| Satralizumab | Myopathies | Phase 2 | NCT06450639 | SHIELD DMD — A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) | ACTIVE_NOT_RECRUITING |
| Erenumab Dose 1 | Migraine | Phase 3 | NCT03836040 | OASIS(EM) — Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine | ACTIVE_NOT_RECRUITING |